Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Inhaled corticosteroids for subacute and chronic cough in adults (Review)

Johnstone, Kate J., Chang, Anne B., Fong, Kwun M., Bowman, Rayleen V. and Yang, Ian A. (2013). Inhaled corticosteroids for subacute and chronic cough in adults (Review). Cochrane Database of Systematic Reviews,2013(3 - Article No. CD009305).

Document type: Journal Article
Citation counts: Altmetric Score Altmetric Score is 7
Google Scholar Search Google Scholar
Attached Files (Some files may be inaccessible until you login with your CDU eSpace credentials)
Name Description MIMEType Size Downloads
Download this reading Chang_38501.pdf Published version application/pdf 1.24MB 603
Reading the attached file works best in Firefox, Chrome and IE 9 or later.

Title Inhaled corticosteroids for subacute and chronic cough in adults (Review)
Author Johnstone, Kate J.
Chang, Anne B.
Fong, Kwun M.
Bowman, Rayleen V.
Yang, Ian A.
Journal Name Cochrane Database of Systematic Reviews
Publication Date 2013
Volume Number 2013
Issue Number 3 - Article No. CD009305
ISSN 1469-493X   (check CDU catalogue open catalogue search in new window)
Total Pages 86
Place of Publication United Kingdom
Publisher John Wiley & Sons Ltd.
Abstract Background
Persistent cough is a common clinical problem. Despite thorough investigation and empirical management, a considerable proportion of those people with subacute and chronic cough have unexplained cough, for which treatment options are limited. While current guidelines recommend inhaled corticosteroids (ICS), the research evidence for this intervention is conflicting.

Objectives
To assess the effects of ICS for subacute and chronic cough in adults.

Search methods
We searched the Cochrane Airways Group Register of Trials, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and ClinicalTrials.gov in December 2012 and conducted handsearches.
Selection criteria
Two authors independently assessed all potentially relevant trials. All published and unpublished randomised comparisons of ICS versus placebo in adults with subacute or chronic cough were included. Participants with known chronic respiratory disease and asthma were excluded. Studies of cough-variant asthma and eosinophilic bronchitis were eligible.

Data collection and analysis
Two authors independently extracted data pertaining to pre-defined outcomes. The primary outcome was the proportion of participants with clinical cure or significant improvement (over 70% reduction in cough severity measure) at follow up (clinical success). The secondary outcomes included proportion of participants with clinical cure or over 50% reduction in cough severity measure at follow up, mean change in cough severity measures, complications of cough, biomarkers of inflammation and adverse effects. We requested additional data from study authors.

Main results
Eight primary studies, including 570 participants, were included. The overall methodological quality of studies was good. Significant clinical heterogeneity resulting from differences in participants and interventions, as well as variation in outcome measures, limited the validity of comparisons between studies for most outcomes. Data for the primary outcome of clinical cure or significant (> 70%) improvement were available for only three studies, which were too heterogeneous to pool. Similarly, heterogeneity in study characteristics limited the validity of meta-analysis for the secondary outcomes of proportion of participants with clinical cure or over 50% reduction in cough severity measure and clinical cure. One parallel group trial of chronic cough which identified a significant treatment effect contributed the majority of statistical heterogeneity for these outcomes. While ICS treatment resulted in a mean decrease in cough score of 0.34 standard deviations (SMD -0.34; 95% CI -0.56 to -0.13; 346 participants), the quality of evidence was low. Heterogeneity also prevented meta-analysis for the outcome of mean change in visual analogue scale score. Meta-analysis was not possible for the outcomes of pulmonary function, complications of cough or biomarkers of inflammation due to insufficient data. There was moderate quality evidence that treatment with ICS did not significantly increase the odds of experiencing an adverse event (OR 1.67; 95% CI 0.92 to 3.04).

Authors' conclusions
The studies were highly heterogeneous and results were inconsistent. Heterogeneity in study design needs to be addressed in future research in order to test the efficacy of this intervention. International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.
DOI http://dx.doi.org/10.1002/14651858.CD009305.pub2   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)


© copyright

Every reasonable effort has been made to ensure that permission has been obtained for items included in CDU eSpace. If you believe that your rights have been infringed by this repository, please contact digitisation@cdu.edu.au.

 
Versions
Version Filter Type
Access Statistics: 75 Abstract Views, 603 File Downloads  -  Detailed Statistics
Created: Fri, 31 Jan 2014, 15:16:04 CST by Iwona Rohoza